Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat

Exact Sciences Corporation (EXAS) reported a net loss of 9 cents per share in second-quarter 2024, narrower than the year-ago loss of 45 cents per share. The figure beat the Zacks Consensus Estimate of a loss of 37 cents per share.Q2 RevenuesConsolidated revenues totaled $699.3 million, up 12.4% on a reported basis and 13% on a core revenue basis. The figure beat the Zacks Consensus Estimate by 1.6%.Segments in DetailScreening revenues, including laboratory service revenues from Cologuard and PreventionGene ...